论文部分内容阅读
目的:探究进展期鼻咽癌使用西妥昔单抗联合放化疗治疗的临床效果。方法:选取我院2016年5月-2017年5月收治的进展期鼻咽喉患者160例作为研究对象,随机分为观察组和对照组,每组各80例。对照组给予放化疗治疗。观察组在对照组的基础上联用西妥昔单抗治疗。比较两组患者的治疗效果。结果:观察组的患者治疗总有效率为93.75%明显高于对照组的患者治疗总有效率62.5%,差异明显具有统计学意义(P<0.05);观察组的不良反应发生率52.5%与对照组的不良反应发生率31.25%,观察组显著高于对照组,差异明显具有统计学意义(P<0.05)。结论:西妥昔单抗联合放化疗治疗进展期鼻咽癌的近期效果显著,可是不良反应比较多,临床上需要综合考量之后进行推广使用。在治疗期间需要对患者的不良反应进行紧密关注,同时将护理工作做好,减少不良反应给患者带来的影响。
Objective: To investigate the clinical effect of cetuximab combined with radiotherapy and chemotherapy in advanced nasopharyngeal carcinoma. Methods: One hundred and sixty patients with advanced nasopharyngeal throat treated in our hospital from May 2016 to May 2017 were selected and randomly divided into observation group and control group, 80 cases in each group. The control group received radiotherapy and chemotherapy. The observation group was treated with cetuximab on the basis of the control group. The treatment effect of two groups of patients was compared. Results: The total effective rate of the observation group was 93.75%, which was significantly higher than that of the control group (62.5%), the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 52.5% The adverse reaction rate was 31.25% in the observation group and significantly higher than that in the control group (P <0.05). Conclusion: Cetuximab combined with radiotherapy and chemotherapy for the treatment of advanced nasopharyngeal carcinoma has a significant short-term effect, but more adverse reactions, the need for comprehensive consideration of the clinical promotion. During the treatment of adverse reactions need to pay close attention to patients, while nursing work well to reduce the adverse reaction to the impact of patients.